IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2021

 
Micro RNAs Promoting Growth and Metastasis in Preclinical In Vivo Models of Subcutaneous Melanoma. U.H. WEIDLE, S. AUSLÄNDER, U. BRINKMANN (Penzberg, Germany). Cancer Genomics Proteomics 17:651-667, 2020.
Micro RNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical In Vivo Models. U.H. WEIDLE, U. BRINKMANN, S. AUSLAENDER (Penzberg, Germany). Cancer Genomics Proteomics 17:453-468, 2020.
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. A. RIZZO, A.D. RICCI, S. TAVOLARI, G. BRANDI (Bologna, Italy). Cancer Genomics Proteomics 17:441-452, 2020.
Anticancer Effects of Nutraceuticals in the Mediterranean Diet: An Epigenetic Diet Model. R. DIVELLA, A. DANIELE, E. SAVINO, A. PARADISO (Bari, Italy). Cancer Genomics Proteomics 17:335-350, 2020.
Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models. U.H. WEIDLE, A. NOPORA (Penzberg, Germany). Cancer Genomics Proteomics 17:321-334, 2020.
MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. U.H. WEIDLE, D. SCHMID, F. BIRZELE, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 17:1-21, 2020.
MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer. U.H. WEIDLE, F. BIRZELE, A. NOPORA (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 16: 99-119, 2019.
The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs. U.H. WEIDLE, A. EPP, F. BIRZELE, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 16: 1-19, 2019
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. O. ROMANIDOU, V. KOTOULA, G. FOUNTZILAS (Thessaloniki, Greece). Cancer Genomics Proteomics 15: 421-436, 2018.
Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors. U.H. WEIDLE, F. BIRZELE, G. TIEFENTHALER (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 15: 225-238, 2018.
Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. D. MORIS, I. NTANASIS-STATHOPOULOS, D.I. TSILIMIGRAS, M.A. ADAM, C.J. YANG, D. HARPOLE, S. THEOCHARIS (Durham, NC, USA; Athens, Greece). Cancer Genomics Proteomics 15: 153-163, 2018.
Applications of Support Vector Machine (SVM) Learning in Cancer Genomics. S. HUANG, N. CAI, P. PENZUTI PACHECO, S. NARANDES, Y. WANG, W. XU (Winnipeg, Canada). Cancer Genomics Proteomics 15: 41-51, 2018.
The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. U.H. WEIDLE, S. DICKOPF, C. HINTERMAIR, G. KOLLMORGEN, F. BIRZELE, U. BRINKMANN (Penzberg; Munich, Germany; Basel, Switzerland). Cancer Genomics Proteomics 15: 17-39, 2018.
Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, A. NOPORA (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 15: 1-15, 2018.
Impact of Mediterranean Diet on Cancer: Focused Literature Review. Y. BARAK, D. FRIDMAN (Dunedin; Wellington, New Zealand). Cancer Genomics Proteomics 14: 403-408, 2017.
Chemical Proteomic Approaches Targeting Cancer Stem Cells: A Review of Current Literature. H.J. JUNG (Asan, Republic of Korea). Cancer Genomics Proteomics 14: 315-327, 2017.
Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises. N. GARMPIS, C. DAMASKOS, A. GARMPI, E. KALAMPOKAS, T. KALAMPOKAS, E. SPARTALIS, A. DASKALOPOULOU, S. VALSAMI, M. KONTOS, A. NONNI, K. KONTZOGLOU, D. PERREA, N. NIKITEAS, D. DIMITROULIS (Athens, Greece; Aberdeen, UK). Cancer Genomics Proteomics 14: 299-313, 2017.
The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2. C.M. PFEFFER, B.N. HO, A.T.K. SINGH (Kenosha, WI, USA). Cancer Genomics Proteomics 14: 293-298, 2017.
Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review. Y.-C.C. LAI, C.-C. CHENG, Y.-S. LAI, Y.-H. LIU (Kaohsiung; Changhua; Taichung; Hualien, Taiwan, ROC). Cancer Genomics Proteomics 14: 219-223, 2017
The Warburg Effect and Mass Spectrometry-based Proteomic Analysis. W. ZHOU, L.A. LIOTTA, E.F. PETRICOIN (Manassas, VA, USA). Cancer Genomics Proteomics 14: 211-218, 2017.
Long Non-coding RNAs and their Role in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 14: 143-160, 2017.
Monochromosomal Hybrids and Chromosome Transfer: A Functional Approach for Gene Identification. R.P. KANDPAL, A.K. SANDHU, G. KAUR, G.P. KAUR, R.S. ATHWAL (Pomona, CA; Philadelphia, PA, USA). Cancer Genomics Proteomics 14: 93-101, 2017.
The Multiple Roles of Exosomes in Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 14: 1-15, 2017.
Clinical and Therapeutic Implications of Follistatin in Solid Tumours. L. SHI, J. RESAUL, S. OWEN, L. YE, W.G. JIANG (Yantai, Shandong, PR China; Cardiff, UK). Cancer Genomics Proteomics 13: 425-435, 2016.
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RUEGER (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 13: 407-423, 2016.
Human Uterine Cervical Stromal Stem Cells (hUCESCs): Why and How they Exert their Antitumor Activity. J. SCHNEIDER, N. EIRÓ, R. PÉREZ-FERNÁNDEZ, A. MARTÍNEZ-ORDÓÑEZ, F. VIZOSO (Valladolid; Gijón; Santiago de Compostela, Spain). Cancer Genomics Proteomics 13: 331-337, 2016.
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. M. MEDINGER, C. LENGERKE, J. PASSWEG (Basel, Switzerland). Cancer Genomics Proteomics 13: 317-329, 2016.
Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Penzberg, Germany; Basel, Switzerland). Cancer Genomics Proteomics 13: 245-258, 2016.
The Significance of Proteomic Biomarkers in Male Breast Cancer. E. ZOGRAFOS, M. GAZOULI, G. TSANGARIS, E. MARINOS (Athens, Greece). Cancer Genomics Proteomics 13: 183-190, 2016.
Molecular Basis of Lung Tropism of Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Penzberg, Germany). Cancer Genomics Proteomics 13: 129-139, 2016.
Molecular Mechanisms of Bone Metastasis. U.H. WEIDLE, F. BIRZELE, G. KOLLMORGEN, R. RÜGER (Penzberg, Germany). Cancer Genomics Proteomics 13: 1-12, 2016.
Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer. F. LUMACHI, G.B. CHIARA, L. FOLTRAN, S.M.M. BASSO (Padova; Pordenone, Italy). Cancer Genomics & Proteomics 12: 385-390, 2015.
Ensuring Sample Quality for Biomarker Discovery Studies – Use of ICT Tools to Trace Biosample Lifecycle. S. RIONDINO, P. FERRONI, A. SPILA, J. ALESSANDRONI, R. D’ALESSANDRO, V. FORMICA, D. DELLA-MORTE, R. PALMIROTTA, U. NANNI, M. ROSELLI, F. GUADAGNI (Rome, Italy). Cancer Genomics & Proteomics 12: 291-299, 2015.
The Blood–Brain Barrier Challenge for the Treatment of Brain Cancer, Secondary Brain Metastases, and Neurological Diseases. U.H. WEIDLE, J. NIEWÖHNER, G. TIEFENTHALER (Penzberg, Germany). Cancer Genomics & Proteomics 12: 167-177, 2015.
Caveolin-1, Breast Cancer and Ionizing Radiation. M. PUCCI, V. BRAVATÀ, G.I. FORTE, F.P. CAMMARATA, C. MESSA, M.C. GILARDI, L. MINAFRA (Cefalù; Milan; Monza, Italy). Cancer Genomics & Proteomics 12: 143-152, 2015.
TCR-MHC/Peptide Interaction: Prospects for new Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (Penzberg, Germany). Cancer Genomics & Proteomics 11: 267-277, 2014.
Tumor Interstitial Fluid: Proteomic determination as a Possible Source of Biomarkers. G. BARONZIO, G. PARMAR, M. BARONZIO, M. KISELEVSKY (Milan, Terni, Italy; Fort Langley, BC, Canada; Moscow, Russia). Cancer Genomics & Proteomics 11: 225-237, 2014.
Current State of mTOR Targeting in Human Breast Cancer. U. WAZIR, A. WAZIR, Z.S. KHANZADA, W.G. JIANG, A.K. SHARMA, K. MOKBEL (London; Cardiff, Wales, UK; Karachi, Pakistan). Cancer Genomics & Proteomics 11: 167-174, 2014.
Structure and Role of WASP and WAVe in Rho GTPase Signalling in Cancer. J. LANE, T. MARTIN, H.P. WEEKS, W.G. JIANG (Cardiff, UK). Cancer Genomics & Proteomics 11: 155-165, 2014.
Proteases as Activators for Cytotoxic Prodrugs in Antitumor Therapy. U.H. WEIDLE, G. TIEFENTHALER, G. GEORGES (Penzberg, Germany). Cancer Genomics & Proteomics 11: 267-79, 2014.
Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-Review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.-C. CHO, J. WANG, Y.-G MAN (Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou; Hong Kong, P.R. China). Cancer Genomics & Proteomics 11: 57-65, 2014.
Prospects of Bacterial and Plant Protein-based Immunotoxins for Treatment of Cancer. U.H. WEIDLE, G. TIEFENTHALER, C. SCHILLER, E.H. WEISS, G. GEORGES, U. BRINKMANN (Penzberg; Munich, Germany). Cancer Genomics & Proteomics 11: 25-38, 2014.
The Translational Potential for Target Validation and Therapy Using Intracellular Antibodies in Oncology.
U.H. WEIDLE, D. MAISEL, U. BRINKMANN, G. TIEFENTHALER (Penzberg, Germany). Cancer Genomics & Proteomics 10: 239-250, 2013.
Genomics and Proteomics Approaches for Biomarker Discovery in Sporadic Colorectal Cancer with Metastasis.
M. GONZÁLEZ-GONZÁLEZ, J. GARCIA GARCIA, J.A. ALCAZAR MONTERO, L.M. GONZÁLEZ FERNANDEZ, O. BENGOECHEA, O. BLANCO MUÑEZ, A. ORFAO, J.M. SAYAGUES, M. FUENTES (Salamanca, Spain). Cancer Genomics & Proteomics 10: 19-26, 2013.
The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer.
U.H. WEIDLE, G. TIEFENTHALER, E.H. WEISS, G. GEORGES, U. BRINKMANN (Penzberg; Munich, Germany). Cancer Genomics & Proteomics 10: 1-18, 2013.
Cancer Metabolism: What we Can Learn from Proteomic Analysis by Mass Spectrometry.
W. ZHOU, L.A. LIOTTA, E.F. PETRICOIN (Manassas, VA, USA). Cancer Genomics & Proteomics 9: 373-382, 2012.
Genetically Engineered Fusion Proteins for Treatment of Cancer.
U.H. WEIDLE, B. SCHNEIDER, G. GEORGES, U. BRINKMANN (Penzberg, Germany). Cancer Genomics & Proteomics 9: 357-372, 2012.
Metastatic Biomarker Discovery Through Proteomics.
L.T. BRINTON, T.A. BRENTNALL, J.A. SMITH, K.A. KELLY (Charlottesville, VA; Seattle, WA, USA). Cancer Genomics & Proteomics 9: 345-356, 2012.
Metastasis from Oral Cancer: An Overview.
J. NOGUTI, C.F. DE MOURA, G.P. DE JESUS, V.H. DA SILVA, T.A. HOSSAKA, C.T. OSHIMA, D.A. RIBEIRO (Sao Paulo, Brazil). Cancer Genomics & Proteomics 9: 329-336, 2012.
Breast Cancer Metastasis.
O.J. SCULLY, B.-H. BAY, G. YIP, Y. YU (Singapore, Singapore). Cancer Genomics & Proteomics 9: 311-320, 2012.
Breast Cancer and Metastasis: On the Way Toward Individualized Therapy.
A.P. TRAPÉ, A.M. GONZALEZ-ANGULO (Houston, TX, USA). Cancer Genomics & Proteomics 9: 297-310, 2012.
Are we Missing the Target? – Cancer Stem Cells and Drug Resistance in Non-small Cell Lung Cancer.
S. GOTTSCHLING, P.A. SCHNABEL, F.J.F. HERTH, E. HERPEL (Heidelberg, Germany). Cancer Genomics & Proteomics 9: 275-286, 2012.
The Spectra Count Label-free Quantitation in Cancer Proteomics.
W. ZHOU, L.A. LIOTTA, E.F. PETRICOIN (Manassas, VA, USA). Cancer Genomics & Proteomics 9: 135-, 2012.
Fully Human Targeted Cytotoxic Fusion Proteins: New Anticancer Agents on the Horizon.
U.H. WEIDLE, G. GEORGES, U. BRINKMANN (Penzberg, Germany). Cancer Genomics & Proteomics 9: 119-134, 2012.
Dissection of Aberrant GPCR Signaling in Tumorigenesis – A Systems Biology Approach.
J. WU, N. XIE, X. ZHAO, E.C. NICE, C. HUANG (Chengdu, PR China; Clayton, VIC, Australia). Cancer Genomics & Proteomics 9: 37-50, 2012.
The Cancer Biomarker Osteopontin: Combination with Other Markers.
G.F. WEBER (Cincinnati, OH, USA). Cancer Genomics & Proteomics 8: 263-288, 2011.
Differential Splicing Generates New Transmembrane Receptor and Extracellular Matrix-related Targets for Antibody-based Therapyof Cancer.
U.H. WEIDLE, D. MAISEL, S. KLOSTERMANN, E.H. WEISS, M. SCHMITT (Penzberg; Planegg-Martinsried;Munich, Germany). Cancer Genomics & Proteomics 8: 211-226, 2011.
Synthetic Lethality-based Targets for Discovery of New Cancer Therapeutics.
U.H. WEIDLE, D. MAISEL, D. EICK (Penzberg; Munich, Germany). Cancer Genomics & Proteomics 8: 159-172, 2011.
Intracellular Proteins Displayed on the Surface of Tumor Cells as Targets for Therapeutic Intervention with Antibody-related Agents.
U.H. WEIDLE, D. MAISEL, S. KLOSTERMANN, C. SCHILLER, E.H. WEISS (Penzberg; Munich, Germany). Cancer Genomics & Proteomics 8: 49-64, 2011.
Interleukin 6/Interleukin 6 Receptor Interaction and its Role as a Therapeutic Target for Treatment of Cachexia and Cancer.
U.H. WEIDLE, S. KLOSTERMANN, D. EGGLE, A. KRÜGER (Penzberg; Munich, Germany). Cancer Genomics & Proteomics 7: 287-302, 2010.
ALCAM/CD166: Cancer-related Issues.
U.H. WEIDLE, D. EGGLE, S. KLOSTERMANN, G.W.M. SWART (Penzberg, Germany; Nijmegen, Netherlands). Cancer Genomics & Proteomics 7: 231-244, 2010.
TGF-β1 Interactome: Metastasis and Beyond.
M. PERERA, C.S. TSANG, R.J. DISTEL, J.N. LACY, L. OHNO-MACHADO, V. RICCHIUTI, L.P. SAMARANAYAKE, G.B. SMEJKAL, M.G. SMITH, A.J. TRACHTENBERG, W.P. KUO (Hong Kong, Hong Kong; Boston, MA; Ormond Beach, FL; La Jolla, CA, USA). Cancer Genomics & Proteomics 7: 217-230, 2010.
Cancer-related Issues of CD147.
U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN,H. STOCKINGER (Penzberg, Germany; Vienna, Austria). Cancer Genomics & Proteomics 7: 157-170, 2010.
The Role of Folate Metabolism-related Gene Polymorphisms in the Development of Meningiomas.
S.S. DRAKOS, F. ANIFANTAKI, A. ZARROS, C. LIAPI (Athens, Greece). Cancer Genomics & Proteomics 7: 105-109, 2010.
Genetic Basis and Gene Therapy Trials for Thyroid Cancer.
H. AL-HUMADI, A. ZARROS, R. ALSAIGH, C. LIAPI (Athens, Greece). Cancer Genomics & Proteomics 7: 31-50, 2010.
The Continuing Search For Predisposing Colorectal Cancer Variants.
S. PICELLI, S. VON HOLST, P. WESSENDORF (Stockholm, Sweden). Cancer Genomics & Proteomics 6: 305-316, 2009.
Pathogenetic and Clinical Relevance of MicroRNAs in Colorectal Cancer.
N. VALERI, C.M. CROCE, M. FABBRI (Columbus, OH, USA; Ferrara, Meldola, Italy). Cancer Genomics & Proteomics 6: 195-204, 2009.
Molecular Profiling for the Identification of New Biomarkers in Smokers and Cancer Patients.
K. ALBERMANN, S. LANG, R. ZEIDLER (Essen; Munich, Germany). Cancer Genomics & Proteomics 4: 349-358, 2007.
Collagen – A Necessary Accomplice in the Metastatic Process.
P.S. NERENBERG, R. SALSAS-ESCAT, C.M. STULTZ (Cambridge, MA, USA). Cancer Genomics & Proteomics 4: 319-328, 2007.
Interpreting Microarray Data: Towards the Complete Bioinformatics Toolkit for Cancer.
M.L. ROBERTS, S.D. KOTTARIDIS (Athens, Greece). Cancer Genomics & Proteomics 4: 301-308, 2007.
Drug Transporters as Targets for Cancer Chemotherapy. T. NAKANISHI (Baltimore, MD, USA). Cancer Genomics & Proteomics 4: 241-254, 2007.
Molecular Targets in Metastasis: Lessons from Genomic Approaches.
B. FINGLETON (Nashville, TN, USA). Cancer Genomics & Proteomics 4: 211-222, 2007.
Tailoring-targeted Therapy to Individual Patients: Lessons to be Learnt from the Development of Mitomycin C.
M. VOLPATO, R.M. PHILLIPS (Bradford, UK). Cancer Genomics & Proteomics 4: 175-186, 2007.
Cancer Stem Cells and Individualized Therapy.
S. CHUMSRI, P. PHATAK, M.J. EDELMAN, N. KHAKPOUR, A.W. HAMBURGER, A.M. BURGER (Baltimore, MD, USA). Cancer Genomics & Proteomics 4: 165-174, 2007.
Development of Reverse Phase Protein Microarrays for Clinical Applications and Patient-tailored Therapy.
R. SPEER, J. WULFKUHLE, V. ESPINA, R. AURAJO, K.H. EDMISTON, L.A. LIOTTA, E.F. PETRICOIN III (Tübingen, Germany; Manassas; Falls Church, VA, USA). Cancer Genomics & Proteomics 4: 157-164, 2007.
Individualization of Therapy Using Mammaprint®TM: from Development to the MINDACT Trial.
S. MOOK, L.J. VAN’T VEER, E.J.T. RUTGERS, M.J. PICCART-GEBHART, F. CARDOSO (Amsterdam, The Netherlands; Brussels, Belgium). Cancer Genomics & Proteomics 4: 147-156, 2007.
Application of Array-based Genomic and Epigenomic Technologies to Unraveling the Heterogeneous Nature of Breast Tumors: On the Road to Individualized Treatment.
M. ABRAMOVITZ, B. LEYLAND-JONES (Montreal, QC, Canada; Atlanta, GA, USA). Cancer Genomics & Proteomics 4: 135-146, 2007.
Contribution of DNA and Tissue Microarray Technology to the Identification and Validation of Biomarkers and Personalised Medicine in Breast Cancer.
D.J. BRENNAN, C. KELLY, E. REXHEPAJ, P.A. DERVAN, M.J. DUFFY, W.M. GALLAGHER (Dublin, Ireland). Cancer Genomics & Proteomics 4: 121-134, 2007.
Basics of Diagnostic DNA Microarray Technology. Case Study: Hepatocellular Carcinoma.
A. EL-ANEED, J. BANOUB (St. John’s, NL, Canada). Cancer Genomics & Proteomics 3: 311-316, 2006.
Proteomics in Cancer Research and Diagnosis; An Update.
V. IFANDI, S.E. SLADE, M. KHAN (Coventry, UK). Cancer Genomics & Proteomics 3: 253-264, 2006.
Considerations Regarding the Use of Blood Samples in the Proteomic Identification of Biomarkers for Cancer Diagnosis.
C.V. SAPAN, R.L. LUNDBLAD (Chapel Hill, NC, USA). Cancer Genomics & Proteomics 3: 227-230, 2006.
Laser Microdissection: Application to Carcinogenesis.
F.E. AHMED (Greenville, NC, USA). Cancer Genomics & Proteomics 3: 217-226, 2006.
Metastasis Promoter S100A4 is a Potential Molecular Therapeutic Target.
G.V. SHERBET (Newcastle upon Tyne, UK; Huntington Beach, CA, USA). Cancer Genomics & Proteomics 3: 203-216, 2006.
Gene Expression Microarray Technology: Some Applications in Lung Cancer Research.
L. BREEN, L. O’DRISCOLL, M. CLYNES (Dublin, Ireland). Cancer Genomics & Proteomics 3: 197-202, 2006.
Molecular Replacement for Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy.
G.L. NICOLSON, K.A. CONKLIN (Huntington Beach; Los Angeles, CA, USA). Cancer Genomics & Proteomics 3: 159-168, 2006.
Design of Nanoparticles as Drug Carriers for Cancer Therapy.
J. ZHANG, C.Q. LAN, M. POST, B. SIMARD, Y. DESLANDES, T.H. HSIEH (Ottawa, ON, Canada). Cancer Genomics & Proteomics 3: 147-158, 2006.
Genomic Instability and Breast Cancer Progression.
S. INGVARSSON (Reykjavik, Iceland). Cancer Genomics & Proteomics 3: 137-146, 2006.
RNA Interference with siRNA.
H. JOYCE, I. BRAY, M. CLYNES (Dublin, Ireland). Cancer Genomics & Proteomics 3: 127-136, 2006.
Proteomics and Bioinformatics in Biomedical Research.
T. KISLINGER, I. JURISICA (Toronto, ON, Canada). Cancer Genomics & Proteomics 3: 11-28, 2006.
Gene Expression and Proteomic Analysis of Pancreatic Cancer: a Recent Update.
R. CHEN, S. PAN, D.A. CRISPIN, T.A. BRENTNALL (Seattle, WA, USA). Cancer Genomics & Proteomics 3: 1-10, 2006.
Quantitative Real-time RT-PCR: Application to Carcinogenesis.
F.E. AHMED (Greenville, NC, USA). Cancer Genomics & Proteomics 2: 317-332, 2005.
Phylogenetics: Applications, Software and Challenges.
A. STAMATAKIS (Heraklion, Greece). Cancer Genomics & Proteomics 2: 301-305, 2005.
Application of Microarrays for the Prediction of Therapy Response in Breast Cancer.
B. GYÖRFFY, P. SUROWIAK, H. LAGE (Berlin, Germany; Budapest, Hungary; Wroclaw, Poland). Cancer Genomics & Proteomics 2: 255-264, 2005.
Tumor Suppressor Genes on Human Chromosome 3 and Cancer Pathogenesis.
S. INGVARSSON (Reykjavik, Iceland). Cancer Genomics & Proteomics 2: 247-254, 2005.
Stathmin in Cell Proliferation and Cancer Progression.
G.V. SHERBET, F. CAJONE (Newcastle-upon-Tyne, U.K.; Huntington Beach, CA, U.S.A.; Milan, Italy). Cancer Genomics & Proteomics 2: 227-238, 2005.
Using Comparative Genomics to Leverage Animal Models in the Identification of Cancer Genes. Examples in Prostate Cancer.
M.W. DATTA, M.A. SUCKOW, S. TWIGGER, M. POLLARD, H. JACOB, P.J. TONELLATO (Atlanta, GA; Notre Dame, IN; Milwaukee, WI, USA). Cancer Genomics & Proteomics 2: 137-144, 2005.

IMPORTANT NOTE: You may submit your article only through our online submission system